Torrance, February 04, 2016 : Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of a 3µm particle size to the company’s newest chiral selector, Lux Amylose-1, amylose tris (3,5-dimethylphenylcarbamate). These high-efficiency Lux polysaccharide columns are ideal for UHPLC, HPLC and SFC chiral screening and analysis, and now with two sizes – the new 3µm and existing 5µm particles – method scalability from analytical work to preparative purification is seamless.
“Our six complementary and highly enantioselective Lux chiral stationary phases in both 3µm and 5µm sizes greatly enhance our customers’ potential for baseline enantiomeric separation,” explained Simon Lomas, strategic marketing manager for Phenomenex. “The Lux 3µm Amylose-1 in particular is an essential chiral screening phase, delivering increased separation power with its broad recognition and high efficiency levels.”
The affordable Lux Amylose-1 provides valuable enantioselectivity and is a guaranteed alternative to other phases with the same chiral selector. The 3µm-particle media is available in analytical columns while the 5µm-particle media is available in both analytical columns and Phenome nex-patented Axia™ preparative column hardware, both of which are stable in normal phase, reversed phase, polar organic and SFC conditions.
The Phenomenex Lux amylose and cellulose chiral column line of six chiral selectors comprise an affordable and complementary kit for chiral separations, featuring high efficiency, excellent loading capacity and pressure stability up to 300 bar in a wide range of conditions. Ideal applications for Lux columns include drug enantiomers from the pharmaceutical sector, chiral pesticide analysis in agrochemical settings, flavor analysis and production from the food industry, fragrance isolation and commercialization in cosmetics and a range of other chiral-chemical raw materials such as intermediates and finished goods.
To complement its comprehensive Lux chiral column line, Phenomenex offers free chiral screening services with greater than 90 percent success rates from its PhenoLogix application development group, along with over 2,000 chiral applications online that are easily searchable by compound structure or name.
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.
Corporate Comm India(CCI Newswire)
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…